저분자 이노베이터용 API CDMO 시장 규모, 점유율, 동향 분석 : 단계 유형별, 고객 유형별, 치료 영역별, 지역별, 부문별 예측(2026-2033년)

Small Molecule Innovator API CDMO Market Summary

The global small molecule innovator API CDMO market size was estimated at USD 26.66 billion in 2025 and is projected to reach USD 43.75 billion by 2033, growing at a CAGR of 6.55% from 2026 to 2033. The market is experiencing growth driven by increasing demand for small molecule drugs, increasing outsourcing trends among pharmaceutical companies and surge in number of clinical trials.

Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are driving global pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. According to the U.S. FDA, 46 novel drugs were approved in 2025, including therapies targeting advanced cancers and rare diseases, while 1 novel drug has been approved so far in 2026. Moreover, according to an article published by the American Chemical Society in January 2024, the U.S. FDA approved 50 new drugs in 2024, marking a notable increase from the 37 approvals in 2022. Thus, small molecule drugs continue to dominate the pharmaceutical industry's drug development pipeline. As pharmaceutical companies focus on developing new small molecule drugs to address various medical needs, they require the services of API CDMOs to manufacture these active ingredients efficiently and cost-effectively.

Furthermore, pharmaceutical companies have been outsourcing small-molecule API production to CDMOs to enhance efficiency, control costs, and accelerate time-to-market. In addition, rising R&D expenses, complex regulatory requirements, and the need for resilient supply chains drive this shift. CDMOs provide specialized expertise, advanced infrastructure, and scalable manufacturing without heavy capital investment, reducing financial and operational risks. Besides this, long-term partnerships also support innovation and global market access. For instance, in August 2025, the U.S. FDA launched FDA PreCheck to strengthen domestic supply chains, as most APIs are sourced overseas and only 11% are U.S.-based. Thus, growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor.

Moreover, the surge in clinical trials globally is fueling demand for small-molecule APIs, driving growth in the CDMO market. As pharmaceutical and biotech companies advance more compounds into preclinical and clinical stages, the need for reliable, scalable API production has intensified. In addition, outsourcing to CDMOs enables firms to meet this growing demand efficiently, leveraging specialized expertise, flexible manufacturing capacity, and regulatory compliance. This trend enables companies to accelerate development timelines and bring novel therapies to market more quickly. Similarly, as of February 2024, the global count of registered clinical trials on ClinicalTrials.gov is 483,592, reflecting a noteworthy increase compared to the reported over 365,000 registered trials in early 2021. Among the current number, 66,206 trials actively recruit participants. This expansion underscores the continual growth of the clinical research landscape. Several factors contribute to the rise in registered studies, including advancements in medical technology, an upsurge in diseases under investigation, and the imperative for novel treatments.

Global Small Molecule Innovator API CDMO Market Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global small molecule innovator API CDMO market based on stage type, customer type, therapeutic area and region:

• Stage Type Outlook (Revenue, USD Million, 2021 - 2033)
• Preclinical
• Clinical
  • Phase I
  • Phase II
  • Phase III
• Commercial
• Customer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical
  • Small
  • Medium
  • Large
• Biotechnology
  • Small
  • Medium
  • Large
• Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)
• Cardiovascular Diseases
• Oncology
• Respiratory Disorders
• Neurology
• Metabolic Disorders
• Infectious Diseases
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Oman
  • Qatar

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Stage Type
  • 1.2.2. Customer Type
  • 1.2.3. Therapeutic Area
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Demand for Small Molecule Drugs
    • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
    • 3.2.1.3. Surge in Number of Clinical Trials
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios in Developing Economies
• 3.3. Technology Landscape
  • 3.3.1. Integration of AI in Small Molecule Innovator API CDMO Market
• 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2025)
  • 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2025)
  • 3.4.2. Total Number of Clinical Trials by Region (2021 - 2025)
  • 3.4.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2025)
• 3.5. Pricing Model Analysis
• 3.6. Tariff Impact Analysis
• 3.7. Value Chain Analysis
  • 3.7.1. Supply Trends
  • 3.7.2. Demand Trends
• 3.8. Market Analysis Tools
  • 3.8.1. Porter's Five Force Analysis
  • 3.8.2. PESTEL by SWOT Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

• 4.1. Small Molecule Innovator API CDMO Market, By Stage Type: Segment Dashboard
• 4.2. Small Molecule Innovator API CDMO Market, By Stage Type: Movement Analysis
• 4.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Stage Type, 2021 - 2033
• 4.4. Preclinical
  • 4.4.1. Preclinical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Clinical
  • 4.5.1. Clinical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Phase I
    • 4.5.2.1. Phase I Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Phase II
    • 4.5.3.1. Phase II Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Phase III
    • 4.5.4.1. Phase III Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Commercial
  • 4.6.1. Commercial Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Phase Estimates & Trend Analysis

• 5.1. Small Molecule Innovator API CDMO Market, By Phase: Segment Dashboard
• 5.2. Small Molecule Innovator API CDMO Market, By Phase: Movement Analysis
• 5.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Phase, 2021 - 2033
• 5.4. Phase I
  • 5.4.1. Phase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Phase II
  • 5.5.1. Phase II Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Phase III
  • 5.6.1. Phase III Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Phase IV
  • 5.7.1. Phase IV Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

• 6.1. Small Molecule Innovator API CDMO Market, By Customer Type: Segment Dashboard
• 6.2. Small Molecule Innovator API CDMO Market, By Customer Type: Movement Analysis
• 6.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Customer Type, 2021 - 2033
• 6.4. Pharmaceutical
  • 6.4.1. Pharmaceutical Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. Small
    • 6.4.2.1. Small Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Medium
    • 6.4.3.1. Medium Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. Large
    • 6.4.4.1. Large Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.5. Biotechnology
  • 6.5.1. Biotechnology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. Small
    • 6.5.2.1. Small Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Medium
    • 6.5.3.1. Medium Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. Large
    • 6.5.4.1. Large Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 7.1. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Segment Dashboard
• 7.2. Small Molecule Innovator API CDMO Market, By Therapeutic Area: Movement Analysis
• 7.3. Small Molecule Innovator API CDMO Market Estimates & Forecasts, By Therapeutic Area, 2021 - 2033
• 7.4. Cardiovascular Diseases
  • 7.4.1. Cardiovascular Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Oncology
  • 7.5.1. Oncology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Respiratory Disorders
  • 7.6.1. Respiratory Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Neurology
  • 7.7.1. Neurology Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Metabolic Disorders
  • 7.8.1. Metabolic Disorders Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.9. Infectious Diseases
  • 7.9.1. Infectious Diseases Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.10. Others
  • 7.10.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2025 & 2033
• 8.3. North America
  • 8.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. U.S
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Canada
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.3.4. Mexico
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. UK
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. Germany
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. France
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Spain
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Denmark
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Sweden
    • 8.4.8.1. Key Country Dynamics
    • 8.4.8.2. Competitive Scenario
    • 8.4.8.3. Regulatory Framework
    • 8.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.4.9. Norway
    • 8.4.9.1. Key Country Dynamics
    • 8.4.9.2. Competitive Scenario
    • 8.4.9.3. Regulatory Framework
    • 8.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. China
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. India
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. South Korea
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.7. Australia
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Brazil
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6.3. Argentina
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. South Africa
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. Saudi Arabia
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. UAE
    • 8.7.4.1. Key Country Dynamics
    • 8.7.4.2. Competitive Scenario
    • 8.7.4.3. Regulatory Framework
    • 8.7.4.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.5. Kuwait
    • 8.7.5.1. Key Country Dynamics
    • 8.7.5.2. Competitive Scenario
    • 8.7.5.3. Regulatory Framework
    • 8.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.6. Oman
    • 8.7.6.1. Key Country Dynamics
    • 8.7.6.2. Competitive Scenario
    • 8.7.6.3. Regulatory Framework
    • 8.7.6.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.7.7. Qatar
    • 8.7.7.1. Key Country Dynamics
    • 8.7.7.2. Competitive Scenario
    • 8.7.7.3. Regulatory Framework
    • 8.7.7.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Lonza Group Ltd.
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Novo Holdings (Catalent, Inc.)
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Thermo Fisher Scientific, Inc.
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Siegfried Holding AG
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Recipharm AB
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. CordenPharma International
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Samsung Biologics
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Labcorp
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Ajinomoto Bio-Pharma Services
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Piramal Pharma Solutions
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Jubilant Life Sciences (Jubilant Biosys Limited)
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. WuXi AppTec Co., Ltd.
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives